Intel stock extends gains after report of possible U.S. government stake
Investing.com - Stifel maintained its Buy rating and $8.00 price target on Rapid Micro Biosystems Inc (NASDAQ:RPID) following the company’s second-quarter results. The target represents a significant upside from the current price of $2.95, though the stock has declined over 21% in the past week. According to InvestingPro analysis, the company maintains a FAIR financial health score of 2.25.
The company reported in-line quarterly performance with strong consumables growth in the mid-teens, according to Stifel’s analysis. Revenue growth reached 22.57% over the last twelve months, though gross margins remain challenged at 7.53%.
Rapid Micro Biosystems adjusted its annual system placement target to the lower end of its previously stated 21-25 instrument range, representing a shift of approximately two units from the mid-point projection.
Stifel noted this adjustment appears "somewhat out of line with the upbeat tone of the commentary on pharma market dynamics and the company’s sales funnel," suggesting potential multi-system order opportunities remain in development.
The research firm highlighted that Rapid Micro Biosystems continues to progress toward product gross margin positivity by year-end, which Stifel views as a positive factor for the company.
In other recent news, Rapid Micro Biosystems released its Q2 2025 financial results, revealing earnings per share (EPS) of -$0.27, which fell just short of the anticipated -$0.26. The company reported revenue of $7.3 million, missing the expected $7.75 million and resulting in a 5.81% negative revenue surprise. Despite achieving a 10% year-over-year increase in revenue, the earnings report did not meet market expectations. The company’s financial performance has drawn attention from investors and analysts alike. These developments indicate ongoing challenges in meeting analyst forecasts, as noted by the revenue and earnings misses. Analysts from various firms are closely monitoring these figures to assess the company’s future performance. The company’s financial results continue to be a focal point for stakeholders evaluating its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.